Navigation Links
Positive Results from Phase IIa Study Pave Way for Phase IIb Trial of DG051 for the Prevention of Heart Attack
Date:1/9/2008

REYKJAVIK, Iceland, Jan. 9 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced positive topline results from its Phase IIa clinical trial for DG051, the company's leukotriene A4 hydrolase inhibitor being developed for the prevention of heart attack. With these results, the company has finalized the design of a Phase IIb trial for which it expects to begin enrolling patients this spring. The company will discuss the development of DG051 and the rest of its product portfolio in its presentation at the JP Morgan 26th Annual Healthcare Conference. The presentation, to be delivered on Thursday January 10 at 11:30am PST/2:30pm EST/7:30pm GMT, will be webcast live via the investors' section of the company's website at http://www.decode.com.

In several studies conducted in healthy volunteers last year, DG051 was shown to reduce the production of leukotriene B4 (LTB4) in a dose-dependent manner. LTB4 is a pro-inflammatory molecule that deCODE's gene discovery and functional biology work identified as a one of the factors modulating risk of heart attack. The results of the double-blind, placebo-controlled Phase IIa study completed last month confirm that DG051 also delivers significant dose- dependent reductions in LTB4 in patients with a history of heart attack or coronary artery disease and who were taking a variety of concomitant medications. The pharmacokinetic and safety profiles of the compound were favorable and similar to those seen in previous studies in healthy volunteers. There were no serious adverse events in the study. The Phase IIb study, that will begin in the spring, will be a 400 patient, double-blind placebo- controlled study further examining its pharm
'/>"/>

SOURCE deCODE genetics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 Valeant ... VRX ) (TSX: VRX) today announced ... at its 2013 annual meeting of ... the vote for the election of ... H. Farmer235,731,9341,964,748Robert A. Ingram233,865,8763,830,806Theo Melas-Kyriazi237,081,508615,174G. Mason ...
(Date:5/21/2013)... CINCINNATI , May 21, 2013  Tom Daulton, CEO ... named Dealmaker of the Year by the Cincinnati ... Daulton, who was nominated by another local top executive who ... the Mammotome® brand from Ethicon Endo-Surgery in March of 2010. ... Deal Maker Awards program, presented by Huntington Bank, on May ...
(Date:5/21/2013)... N.J. , May 21, 2013 /PRNewswire-iReach/ -- The ... in NJ has attracted the greatest number of ... its President, Mark Alexay .  ... plans to attend this year.  The show,s still 4 ... different companies.  This is a big surprise and ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces 2013 Annual Meeting Results 2Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year 2Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year 3Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show 2
... Ellman International, Inc ., a New York based manufacturer ... today announced the appointment of Dennis S. Herman to ... Herman brings over 20 years of sales leadership ...  "Dennis, proven success in leading sales teams to significant ...
... 1, 2011 Lance® Sandwich Crackers is partnering ... support the organization,s efforts to find better treatments and a ... diabetes is an autoimmune disease that can strike at any ... insulin needed to turn food into energy.  People with the ...
Cached Medicine Technology:Ellman International Announces New US Sales Executive 2Lance® Joins JDRF in the Fight Against Type 1 Diabetes 2Lance® Joins JDRF in the Fight Against Type 1 Diabetes 3
(Date:5/21/2013)... MedMar Healing Center announces their participation in the CannaCommunity ... businesses, including MedMar Healing Center, doctors, and clubs, are coming ... to raise food to help area kids who have been ... years. , “We like being able to give back ... Chloupek of MedMar Healing Center. “Taking part in the food ...
(Date:5/21/2013)... (May 21, 2013) Research into genetic features of ... of Colorado School of Medicine may lead to improved ... paper published online by JAMA . , The ... survival in some cases of pulmonary fibrosis, a chronic ... As a result of the study, researchers may want ...
(Date:5/21/2013)... New York, New York (PRWEB) May 21, 2013 ... da Vinci surgery robot lawsuit is nearing its ... According to Bloomberg.com, during closing statements yesterday, an ... car dealership, alleging the company wanted to tie sales ... to do all the training to keep control of ...
(Date:5/21/2013)... 2013 Two executives from human resources ... identify which strategies can be most effective to better ... the members who are taking them, in an upcoming ... “How to Manage Specialty Drugs to Reduce Costs and ... the main driver for rising prescription drug costs, which ...
(Date:5/21/2013)... va (PRWEB) May 21, 2013 ... critical technology and management consulting solutions to the ... of Business Development. In the newly created ... leading all aspects of the firm’s business development ... and proposal management functions, and leading strategies to ...
Breaking Medicine News(10 mins):Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4Health News:Consulting Firm Execs to Discuss Strategies for Effective Management of Specialty Drugs in AIS’s May 30 Webinar 2Health News:Octo Consulting Group Appoints Tracy Denny as Vice President of Business Development 2
... Jenifer Goodwin HealthDay Reporter , THURSDAY, Sept. ... a placebo pill to treat a low libido reported ... is evidence of the powerful and somewhat mysterious mind-body ... Viagra and Cialis revolutionized the treatment of male sexual ...
... Texas is recruiting patients for a Phase III lung ... previously treated patients. The trial will evaluate the ... for the treatment of Non-Small Cell Lung Cancer (NSCLC). ... Cancer Immunotherapy) study is expected to be one of ...
... bacteria that inhabit the intestine provide the environmental trigger ... who are genetically susceptible to inflammatory bowel disease (IBD), ... researchers has found. Inflammatory bowel disease results ... immune system and the microbes that inhabit the intestine. ...
... at Washington University School of Medicine in St. Louis ... the effectiveness of radiation for hard-to-treat cancers. The ... Cancer Institute , focuses on the role of the ... and functioning of blood vessel networks that feed malignant ...
... By Kathleen Doheny HealthDay Reporter , ... smoking in workplaces and public settings seem to show ... is linked with a decline in hospital admissions for ... to tobacco smoke increases the incidence and severity of ...
... -- A new study is helping unravel an enduring mystery ... affected by the disorder than girls. An international team ... and Mental Health in Toronto, examined specific genes in almost ... others with intellectual disability. They then compared that data to ...
Cached Medicine News:Health News:Placebo Pill Gives Boost to Some Women's Sex Drive 2Health News:Bacteria identified that may lead to inflammatory bowel disease in certain individuals 2Health News:Novel target for existing drug may improve success of radiation therapy 2Health News:Novel target for existing drug may improve success of radiation therapy 3Health News:Smoke-Free Laws May Help Kids Breathe Easier 2Health News:Research Sheds Light on Why Autism Is More Prevalent in Boys 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: